A Phase 2 interventional study of ADX-2191 and ADX-2191 in Retinitis Pigmentosa, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 64th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2022, is one of 15 in phase 2, and was the 95th registered.
278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.
Browse Retinitis Pigmentosa studies →20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:
Nacuity Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
Sumitomo Pharma America, Inc. · Sites in United States
Ages 18+
Octant, Inc. · Sites in United States
Ages 18+
Ray Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 38 · Phase 3 11
First in 1993; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.
Median enrollment 21 across the 78 interventional studies, 73 across the 38 observational. Of the 69 that completed or were terminated, 30 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 119 have an industry lead sponsor. The 10 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
Aldeyra Therapeutics, Inc. has 1 study filed under Retinitis Pigmentosa — fewer than ten, so there is no comparison to draw.
11 of the studies in Retinitis Pigmentosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388200Phase 3OcugenA Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | 2027-02-12 |
| NCT06912633jCyte, IncSafety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) | 2026-12 |
| NCT02086890Nova Southeastern UniversityElectro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa | 2026-12 |
| NCT04278131Bionic Sight LLCBS01 in Patients With Retinitis Pigmentosa | 2026-12-30 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 119 studies in Retinitis Pigmentosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: ADX-2191
Drug: ADX-2191
Number of Subjects With Serious Adverse Events
The proportion of subjects that experience at least one serious adverse event
Time frame: The safety assessment period was 16 weeks.
| Milestone | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing |
|---|---|---|
| Started | 4 | 4 |
| Completed | 4 | 4 |
| Not completed | 0 | 0 |
The proportion of subjects that experience at least one serious adverse event
| Participants | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing |
|---|---|---|
| Number of Subjects With Serious Adverse Events | 0 | 0 |
Collected over The safety assessment period was 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-2191 Monthly Dosing | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| ADX-2191 Twice-monthly Dosing | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing |
|---|---|---|
| General disorders and administration site conditionsGeneral disorders | 3/4 | 3/4 |
Safety population
| Age, Categorical(Participants) | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 5 |
| >=65 years | 2 | 1 | 3 |
| Sex: Female, Male(Participants) | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 3 | 7 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 4 | 4 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | ADX-2191 Monthly Dosing | ADX-2191 Twice-monthly Dosing | Total |
|---|---|---|---|
| United States | 4 | 4 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Jun 2023, 11 months.
Results were first posted in Apr 2026, 2 years 10 months after primary completion. A results delay was requested in Apr 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate